Form 4: Apellis CEO Transfers Shares to Irrevocable Trust

Apellis Pharmaceuticals CEO Cedric Francois reported a transfer of 64,869 shares of common stock to an irrevocable trust for estate planning.

Summary

• Cedric Francois, Chief Executive Officer and Director of Apellis Pharmaceuticals, Inc. (APLS), reported a change in beneficial ownership.
• On March 11, 2026, Francois transferred 64,869 shares of Apellis Common Stock from his direct ownership to The Cedric Francois Irrevocable Trust of 2023 2.
• Following this transaction, Francois directly owns 425,968 shares.
• Indirect beneficial ownership includes 372,815 shares through The Cedric Francois Irrevocable Trust of 2023 2, 472,065 shares through The Cedric Francois Irrevocable Trust of 2023, 300,000 shares through The Francois Grossi Trust, and 234,411 shares through The Francois-DuBois Educational Trust.
• Francois disclaims beneficial ownership over shares held by these trusts except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine insider transaction for estate planning purposes rather than a reflection of company performance or strategic shifts.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

StockSavvy.ai notes that transfers of shares to trusts by corporate insiders are common practices for estate planning and wealth management, and typically do not reflect on the operational performance or strategic direction of the company itself.

Comparison to Industry Standards

• NA

Related Party Transactions

• Cedric Francois transferred 64,869 shares to The Cedric Francois Irrevocable Trust of 2023 2, a trust for which he disclaims beneficial ownership except to the extent of his pecuniary interest. Other indirect holdings are through The Cedric Francois Irrevocable Trust of 2023, The Francois Grossi Trust (with spouse as trustee), and The Francois-DuBois Educational Trust.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a change in the form of beneficial ownership by an insider, not a sale into the open market. It does not alter the total outstanding shares or the company's operational fundamentals.
• Employees, Customers, Suppliers, Creditors: No direct impact from this beneficial ownership transfer.

Key Dates

Recommendation

This Form 4 filing details a personal estate planning transaction by the CEO, involving the transfer of shares to a trust. It does not provide information related to the company's operational performance, financial health, or future prospects that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself offers no new fundamental insights for a buy or sell decision.

Keywords

Apellis Pharmaceuticals, APLS, Cedric Francois, Form 4, beneficial ownership, stock transfer, trust, insider transaction